ClinicalTrials.govpublic full text
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
previously untreated symptomatic multiple myeloma, multiple myeloma, autologous stem cell transplant, allogeneic stem cell transplant, lenalidomide, bortezomib, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 826506
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.